0000950170-24-037395.txt : 20240327 0000950170-24-037395.hdr.sgml : 20240327 20240327173905 ACCESSION NUMBER: 0000950170-24-037395 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240325 FILED AS OF DATE: 20240327 DATE AS OF CHANGE: 20240327 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Xu Diyong CENTRAL INDEX KEY: 0001995088 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38433 FILM NUMBER: 24792311 MAIL ADDRESS: STREET 1: 601 LEXINGTON AVE. STREET 2: 54TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Q32 Bio Inc. CENTRAL INDEX KEY: 0001661998 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 473468154 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 830 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 781-999-0232 MAIL ADDRESS: STREET 1: 830 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: Homology Medicines, Inc. DATE OF NAME CHANGE: 20151228 4 1 ownership.xml 4 X0508 4 2024-03-25 0001661998 Q32 Bio Inc. QTTB 0001995088 Xu Diyong Q32 BIO INC. 830 WINTER STREET WALTHAM MA 02451 true false true false false Stock Option (Right to Buy) 16.82 2024-03-25 4 A false 12767 0 A 2034-03-24 Common Stock 12767 12767 D One-third of the shares underlying this option shall vest and become exercisable on March 25, 2025, with the remainder vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VII, LP. /s/ Eric Bell, Attorney-in-Fact 2024-03-27